Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 tria...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847028/
https://www.ncbi.nlm.nih.gov/pubmed/29164421
http://dx.doi.org/10.1007/s10549-017-4518-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847028/
https://www.ncbi.nlm.nih.gov/pubmed/29164421
http://dx.doi.org/10.1007/s10549-017-4518-8

Ejemplares similares